STAT+: As artificial intelligence shows off diagnostic chops, scientists reckon with the way forward

Getting a paper published in Science is a highlight of many researchers’ careers. But for internist and clinical artificial intelligence researcher Adam Rodman, it’s also been a source of some agita. 

On Thursday, Rodman and his colleagues published a compilation of experiments, including one using real-world data from a Boston emergency department, that show a large language model from OpenAI can outperform physicians in case-based diagnostic and clinical reasoning evaluations. To Rodman, the paper’s co-senior author, it’s a response to a gauntlet thrown down in Science in 1959. That paper “described how you would know that a clinical decision support system was capable of doing diagnosis better than humans,” he said. “And they can do it.”

But as generative AI tools like chatbots are heavily marketed — both to patients and clinicians — it makes him worried that the science experiments, all based on simulated and historical cases, will be misconstrued as proof of AI’s safety and efficacy when used to treat real patients. 

Continue to STAT+ to read the full story…

Stem Cell Memory CAR T Therapy Proves Effective at Low Doses

Results from a Phase I clinical trial show promise for a CAR T therapy using a population of stem cell memory T cells (TSCM), achieving complete remission at low doses and lowering the risk of serious adverse effects including cytokine-release syndrome. The study was published in Cell today.

“Seeing patients achieve complete responses at doses as low as 250,000 cells per kilogram, without chemotherapy preconditioning, validates years of preclinical work and opens a new chapter in CAR T-cell design,” says Luca Gattinoni, MD, head of the research division for functional immune cell modulation at the Leibniz Institute for Immunotherapy (LIT) and lead author of the study.

While CAR T therapy has significantly improved treatment of blood cancers, many patients still struggle to experience lasting benefits. One potential cause for this is that the infused CAR T cells can often fail to expand and persist within the body over time. To overcome this challenge, Gattinoni’s team treated patients using a TSCM population with strong self-renewal and proliferation capacity. 

“Today’s CAR T-cell products are heterogeneous, and that variability is reflected in the range of clinical responses and toxicity profiles we see in patients,” explains Gabriele Inchingolo, PhD candidate in Gattinoni’s team and a lead author of the study. “To address this, we developed a highly homogeneous CD8+ CAR T-cell product selectively enriched for TSCM cells and compared its performance to conventional CAR T cells.”

The first-in-human trial recruited patients with relapsed or refractory CD19 B-cell malignancies who had previously received a hematopoietic stem cell transplantation (HSCT), a patient population with very limited therapeutic options. Whether they received conventional CAR T cells or a TSCM-enriched product, no patients received chemotherapy preconditioning, which is typically used before infusing CAR T cells to help the cells engraft.

Compared to standard CAR T cells, the CAR TSCM cells showed greater expansion and persistence, allowing them to achieve complete responses even at low doses. 

“We have shown that a more defined, stem-like cell product can perform effectively at lower doses. By employing a highly homogeneous TSCM population, we can potentially achieve more consistent engraftment and persistence, paving the way for more predictable outcomes and more rationally designed clinical trials,” says Gattinoni.

In addition, the TSCM cells showed a more favorable safety profile. Even at expansion levels that caused severe cytokine-release syndrome in patients treated with conventional CAR T cells, patients treated with the TSCM cells only experienced mild side effects.

“We observed less cytokine-release syndrome in this study compared to most other CAR clinical trials that I have participated in,” adds James Kochenderfer, MD, senior investigator at the surgery branch of the National Cancer Institute (NCI). “The TSCM platform yielded higher CAR T-cell levels on a per cell basis—and across many CAR T-cell studies, high blood CAR T-cell levels have been one of the strongest predictors of clinical efficacy.”

While not every patient responded to the CAR TSCM cell therapy, results showed that treatment failure was driven by external factors such as low levels of the target CD19 protein on tumor cells, immunosuppressive signals such as IL-10, and immune responses against the CAR construct. Future studies in larger cohorts will evaluate the addition of chemotherapy preconditioning and CD4 T cells to potentially continue improving patient outcomes, as well as expanding this approach into other forms of cancer, including solid tumors. 

The post Stem Cell Memory CAR T Therapy Proves Effective at Low Doses appeared first on Inside Precision Medicine.

<![CDATA[A multicenter study tests SAINT TMS for postpartum depression.]]>

This startup’s new mechanistic interpretability tool lets you debug LLMs

The San Francisco–based startup Goodfire just released a new tool, called Silico, that lets researchers and engineers peer inside an AI model and adjust its parameters—the settings that determine a model’s behavior—during training. This could give model makers more fine-grained control over how this technology is built than was once thought possible.

Goodfire claims Silico is the first off-the-shelf tool of its kind that can help developers debug all stages of the development process, from building a data set to training a model.

The company says its mission is to make building AI models less like alchemy and more like a science. Sure, LLMs like ChatGPT and Gemini can do amazing things. But nobody knows exactly how or why they work, and that can make it hard to fix their flaws or block unwanted behaviors. 

“We saw this widening gap between how well models were understood and just how widely they were being deployed,” Goodfire’s CEO, Eric Ho, tells MIT Technology Review in an exclusive chat ahead of Silico’s release. “I think the dominant feeling in every single major frontier lab today is that you just need more scale, more compute, more data, and then you get AGI [artificial general intelligence] and nothing else matters. And we’re saying no, there’s a better way.”

Goodfire is one of a small handful of companies, including industry leaders Anthropic, OpenAI, and Google DeepMind, pioneering a technique known as mechanistic interpretability, which aims to understand what goes on inside an AI model when it carries out a task by mapping its neurons and the pathways between them. (MIT Technology Review picked mechanistic interpretability as one of its 10 Breakthrough Technologies of 2026.)  

Goodfire wants to use this approach not only to audit models—that is, studying those that have already been trained—but to help design them in the first place.  

“We want to remove the trial and error and turn training models into precision engineering,” says Ho. “And that means exposing the knobs and dials so that you can actually use them during the training process.”

Goodfire has already used its techniques and tools to tweak the behaviors of LLMs—for example, reducing the number of hallucinations they produce. With Silico, the company is now packaging up many of those in-house techniques and shipping them as a product.

The tool uses agents to automate much of the complex work. “Agents are now strong enough to do a lot of the interpretability work that we were doing using humans,” says Ho. “That was kind of the gap that needed to be bridged before this was actually a viable platform that customers could use themselves.”

Leonard Bereska, a researcher at the University of Amsterdam who has worked on mechanistic interpretability, thinks Silico looks like a useful tool. But he pushes back on Goodfire’s loftier aspirations. “In reality, they are adding precision to the alchemy,” he says. “Calling it engineering makes it sound more principled than it is.”

Mapping models

Silico lets you zoom in on specific parts of a trained model, such as individual neurons or groups of neurons, and run experiments to see what those neurons do. (Assuming you have access to the model’s inner workings. Most people won’t be able to use Silico to poke around inside ChatGPT or Gemini, but you can use it to look at the parameters inside many open-source models.) You can then check what inputs make different neurons fire, and trace pathways upstream and downstream of a neuron to see how other neurons affect it and how it affects other neurons in turn.

For example, Goodfire found one neuron inside the open-source model Qwen 3 that was associated with the so-called trolley problem. Activating this neuron changed the model’s responses, making it frame its outputs as explicit moral dilemmas. “When this neuron’s active, all sorts of weird things happen,” says Ho.

Pinpointing the source of odd behavior like this is now pretty standard practice. But Goodfire wants to make it easier to adjust that behavior. Using Silico, developers can now adjust the parameters connected to individual neurons to boost or suppress certain behaviors.

In another example, Goodfire researchers asked a model whether a company should disclose that its AI behaves deceptively in 0.3% of cases, affecting 200 million users. The model said no, citing the negative business impact of such a disclosure.

By looking inside the model, the researchers found that boosting neurons that were found to be associated with transparency and disclosure flipped the answer from no to yes nine out of 10 times. “The model already had the ethical reasoning circuitry, but it was being outweighed by the commercial risk assessment,” says Ho.

Tweaking the values of a model in this way is just one approach. Silico can also help steer the training process by filtering out certain training data to avoid setting unwanted values for certain parameters in the first place.   

For example, many models will tell you that 9.11 is greater than 9.9. Looking inside a model to see what’s going on might reveal that it is being influenced by neurons associated with the Bible, in which verse 9.9 comes before 9.11, or by code repositories where consecutive updates are numbered 9.9, 9.10, 9.11 and so on. Using this information, the model can be retrained to make it avoid its “Bible” neurons when doing math.

By releasing Silico, Goodfire wants to put techniques previously available to a few top labs into the hands of smaller firms and research teams that want to build their own model or adapt an open-source one. The tool will be available for a fee determined on a case-by-case basis according to customers’ requirements (Goodfire declined to give specific pricing details).

“If we can make training models a lot more like building software, there’s no reason why there can’t be many more companies designing models that fit their needs,” says Ho.

Bereska agrees that tools like Silico could help firms build more trustworthy models. These techniques could be essential for safety-critical applications in health care and finance, he says.

“Frontier labs already have internal interpretability teams,” he adds. “Silico arms the next tier of companies, where the value is not having to hire interpretability researchers.”

Pathogenic Bacterium Rewires Gut Environment to Colonize and Cause Disease

An international research team headed by scientists at Vanderbilt University Medical Center has shown how an intestinal pathogen reshapes the gut environment to fuel its own colonization and cause disease. The team’s studies found that enterotoxigenic Bacteroides fragilis (ETBF) uses a toxin it produces, Bacteroides fragilis toxin (BTF), to reprogram intestinal cell metabolism and generate conditions that support its growth. ETBF is a classically anaerobic bacterium that causes diarrhea and has been implicated in inflammatory diseases, including colitis and colorectal cancer. The study findings point to potential new therapeutic strategies for disrupting the growth of pathogens such as ETBF.

“Our findings suggest that disease-associated microbes don’t just respond to inflammation—they can actively drive it by reshaping host metabolism,” stated Wenhan Zhu, PhD, assistant professor of pathology, microbiology and immunology. “This opens up new possibilities for intervention, such as by targeting metabolic interactions between host and microbes to prevent or disrupt diseases like infectious diarrhea and colorectal cancer.

Zhu is lead corresponding author of the team’s published paper in Cell, titled “An anaerobic pathogen rewires host metabolism to fuel oxidative growth in the inflamed gut.” In their paper the team wrote, “Here, we demonstrate that ETBF leverages its virulence factor, BFT, to reprogram epithelial cell metabolism, thereby reshaping the gut nutritional landscape. This reprogramming leads to increased levels of lactate and oxygen, which fuel ETBF’s unique oxidative metabolism.”

Independent studies have implicated ETBF in both inflammatory diarrheal diseases and in colorectal cancer, the authors noted. “These pathogenic effects are primarily driven by the virulence factor Bacteroides fragilis toxin (BFT), which elicits a range of physiological alterations in host cells.” However, the team noted, “… the specific mechanisms by which BFT facilitates ETBF niche establishment and promotes persistent colonization in the gut remain largely undefined.”

Zhu has long been interested in how pathogens succeed in the competitive intestinal environment. “The gut is one of the most densely populated microbial environments in the body, with heavy competition for nutrients, yet certain microbes can still take hold and drive disease,” he said. “These microbes are ultimately competing for nutrients, and processes like inflammation and cancer may be ways they alter the environment to gain access to those resources.”

Though the percentage of people who carry ETBF varies from study to study, it can be a common member of the gut microbiota and is considered a classical anaerobe, a type of bacteria that requires low-oxygen conditions (such as those in the large intestine) to survive. It produces a toxin, BFT, that interacts with intestinal host cells, causing inflammation and increasing oxygen and oxidative stress—conditions that are usually harmful to anaerobes such as ETBF.

Zhu and colleagues are exploring how ETBF navigates and exploits these conditions, to gain insight into microbial physiology and host-microbe interactions, he said. Through their newly reported study the investigators found that ETBF uses its toxin, BFT, to reprogram intestinal epithelial cell metabolism.

The researchers discovered that ETBF reshapes the intestinal landscape in unexpected ways, for example by driving epithelial cell proliferation and manipulating immune signaling pathways and bile acid biology. “BFT manipulates colonic epithelial signaling and the bile acid recycling pathway, inducing a metabolic shift in the epithelium from oxidative phosphorylation to glycolysis,” they wrote.

This metabolic shift reduces oxygen consumption by host cells, increasing oxygen availability in the gut. The resulting environment supports the growth of ETBF, despite it being traditionally considered an anaerobe. “This shift increases local concentrations of lactate and oxygen, nutrients that support oxidative metabolism in ETBF,” they continued. These changes also create conditions that promote disease-associated microbial communities linked to colorectal cancer.

“One of our most surprising findings was that a classically anaerobic bacterium can benefit from, and even help create, an oxygen-rich environment,” Zhu said. “This challenges the traditional view that anaerobic microbes simply cannot tolerate oxygen.”

The team is continuing to explore how ETBF modifies its environment to successfully colonize and cause disease; how broadly the mechanisms apply across other microbes and disease settings; and whether these interactions can be therapeutically targeted. In their report the investigators stated, “… by sculpting an oxidative niche, ETBF both fuels its own growth and suppresses its microbial competitors. Importantly, this distinct metabolic program could potentially be leveraged to selectively target and remove ETBF.” Zhu added, “Ultimately, we hope to identify strategies to disrupt these disease-promoting niches before they lead to long-term pathology.”

The post Pathogenic Bacterium Rewires Gut Environment to Colonize and Cause Disease appeared first on GEN – Genetic Engineering and Biotechnology News.

The State of Precision Medicine

Panelists:

Image of Becky Quick

Becky Quick

Anchor
CNBC’s Squawk Box

Panelist

Image of Becky Quick

Becky Quick

Becky Quick is an anchor of CNBC’s popular morning show, Squawk Box, and an award-winning journalist and broadcaster. More importantly, she is the mother of a child with the rare genetic disease, SYNGAP1. The disease, which affects about 1,700 people globally, is derived from a mutation in the SynGAP protein, which is required for brain development. Becky’s daughter Kaylie was diagnosed at three years old, which opened doors to form connections with other families in the rare disease space who are facing similar situations. Becky was the driving force behind the formation of CNBC Cures, hosting and moderating the inaugural summit in New York City in March 2026. The summit featured numerous experts and commentators in rare disease therapeutics and personalized medicine sharing ideas to expedite funding and research for rare genetic disorders.

Becky holds a degree in political science from Rutgers University. Prior to her role as a CNBC anchor, she was a columnist at Fortune and a reporter at the Wall Street Journal.

Image of Anne Wojcicki

Anne Wojcicki

CEO
23andMe Research Institute

Panelist

Image of Anne Wojcicki

Anne Wojcicki

Anne Wojcicki is the founder and CEO of 23andMe and the TTAM Research Institute. She is committed to putting individuals at the center of their health information and decisions with choice and transparency, and in turn empowering them to participate in research. Anne co-founded 23andMe in 2006, three years after the first human genome was sequenced. Her goal was to help people access, understand, and benefit from the human genome and fundamentally change healthcare in the process. Although the company filed for bankruptcy in 2025, Anne maintained her interest in steering the company forward. She formed the TTAM Research Institute, a nonprofit medical research organization, to acquire the company for $305 million.

Prior to founding 23andMe, Anne spent a decade on Wall Street investing in healthcare and felt frustrated by a system built around monetizing illness instead of incentivizing prevention. Anne’s vision and persistence powered an industry-first community approach to genetic research. This novel, web-based research model has resulted in thousands of new genetic discoveries and brought personalized medicine to millions of people.

Image of Brian Bigger, PhD

Brian Bigger, PhD

Chair, Advanced Therapeutics
University of Edinburgh, U.K.

Panelist

Image of Brian Bigger, PhD

Brian Bigger, PhD

Brian Bigger, PhD, is the chair of advanced therapeutics at the Institute of Regeneration and Repair at the University of Edinburgh. His group develops innovative gene and cell therapies, especially neurological lysosomal diseases like Hunter syndrome, and brings these treatments to patients. In particular, the focus is on making novel stem cell gene therapies available to patients with neurological diseases and dementias. Brian’s lab has developed three hematopoietic stem cell gene therapies for mucopolysaccharidosis types II and III (MPS II and MPS III). The first therapy developed in the lab (substrate reduction therapy for MPSIII) entered a Phase III clinical trial in mid 2014.

Brian earned his PhD in gene therapy from Imperial College London. After four years developing a stem cell gene therapy approach for hemophilia B at Cancer Research UK, Brian worked on hematopoietic stem cell migration at the National Blood Service and Oxford University.

Image of Carrie Haverty

Carrie Haverty

Vice President of Medical Affairs & Clinical Strategy
Mirvie

Panelist

Image of Carrie Haverty

Carrie Haverty

Carrie Haverty is vice president of medical affairs and clinical strategy at Mirvie, leading efforts to develop the Mirvie RNA platform using a simple blood test to reveal a pregnancy’s unique biology and predict complications months before they occur. Carrie is also the 2026 president of the National Society of Genetic Counselors, having previously served on the board of directors as chair of the membership committee and various other volunteer roles since she was in graduate school.

Carrie earned her graduate degree in genetic counseling from the University of California, Irvine, and she is a Certified Genetic Counselor. She started her career working in high-risk prenatal care and focused on providing broad access to new diagnostic technologies. Her clinical experience served as the foundation for leading cutting-edge product development and commercialization of new technologies at Counsyl, Myriad Genetics, and Miroculus, prior to joining Mirvie.

Broadcast Date: 
  • Time: 

Welcome to the 2026 State of Precision Medicine virtual summit, hosted by Inside Precision Medicine. This year’s summit focuses on the existing gaps in precision medicine as we ask: How do we make treatment equitable and accessible for all patients across the disease continuum?

On June 3rd, the editors of Inside Precision Medicine will feature an outstanding line-up of guests highlighting the challenges and urgency of expanding access to disease therapies and empowering patients and consumers.

Agenda Highlights:

  • Becky Quick, co-anchor of CNBC’s Squawk Box and the founder of CNBC Cures, discusses her own family’s rare disease journey and her prescription to expand access to rare disease therapeutics 
  • Anne Wojcicki, CEO of the 23andMe Research Institute, speaks on the consumer genetics pioneer’s recent renaissance leading the newly re-imagined organization
  • Brian Bigger, PhD, and Rob Wynn, MD, scientists and clinicians at Manchester University, share insights from their work on stem cell gene therapy and its potential to offer hope for patients with rare diseases such as Hunter syndrome. They are joined by Ricky Chu, father of two children with Hunter syndrome, a rare neurodevelopmental disorder 
  • Carrie Haverty, president of the National Society of Genetic Counselors, hosts a panel on the current trends and challenges in genetic counseling 
  • Saralyn Mark, MD, first senior medical advisor to both the Office on Women’s Health within the HHS and NASA, boldly explores lessons in women’s health with her guests Dorit Donoviel, PhD, and Kim Templeton, MD
  • Breakout sessions from the summit sponsors, including 10x Genomics and Illumina 

Registration is entirely free. We look forward to seeing you on June 3.

Produced with support from:

10x Genomics logo

illumina logo

The Download: the North Pole’s future and humanoid data

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.

Digging for clues about the North Pole’s past

In the past, getting to the North Pole involved a treacherous trip through ice many meters thick. But last year, a research vessel encountered open water and thin ice, which created an easy passage. It provided a reminder of how quickly the Arctic is changing. 

Now scientists are digging deep below the seabed to find out if the Arctic Ocean was ever ice-free—and what that could mean for the future of Earth’s northernmost waters. Here’s what they hope to discover.

—Tim Kalvelage

This story is from the latest issue of our print magazine, which is all about nature. Check out the full issue here, and subscribe to get the next one when it lands. 

Humanoid data: 10 Things That Matter in AI Right Now

I was recently invited to join an app that would pay me to film myself doing tasks like putting food in a bowl and microwaving it. Another site asked if I’d like to remotely control a robotic arm to help improve its dexterity. What on earth is happening?

These examples are just part of a growing push by robotics companies to collect data on our movements for training humanoids. As the race for real-world data heats up, our everyday movements are being turned into training data. Read the full story.

—James O’Donnell

Humanoid data is one of our 10 Things That Matter in AI Right Now, a new look at the big ideas, trends, and technologies really worth your attention in the buzzy world of AI.

The must-reads

I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.

1 Google, Microsoft, Amazon, and Meta have all set AI spending records
Collectively, they’re up 71% on the same quarter last year.  (NYT $)
+ Microsoft, Google and Amazon reported big payoffs from the splurge. (FT $)
+ But Meta’s shares slid after its plans spooked investors. (BBC)
+ What even is the AI bubble? (MIT Technology Review)

2 The White House opposes Anthropic’s plan to expand Mythos access
It’s concerned about the model’s cyber risks. (Bloomberg $)
+ And worried that the government will lose compute access. (WSJ $)
+ Anthropic is seeking funding at a valuation over $900 billion. (Bloomberg $)

3 Elon Musk has claimed OpenAI’s leaders “looted the nonprofit”
During testimony, Musk said he “was a fool” for trusting them. (Gizmodo)
+ But he had raised his own concerns about OpenAI’s non-profit status. (The Verge)
+ The case could reshape the AI landscape. (MIT Technology Review)

4 Autonomous vehicles may be worsening
According to emergency first-responders, glitches are increasing. (Wired)

5 OpenAI has abandoned much of its Stargate plan
It will no longer develop its own data centers. (FT $)
+ The project’s compute requirements have been questioned. (MIT Technology Review)

6 A convicted Harvard scientist is rebuilding a brain-computer lab in China
He had previously been named the world’s top chemist. (Reuters $)
+ But was then convicted for lying about payments from China. (NYT $)

7 Families have sued OpenAI over a mass shooter’s use of ChatGPT
They say OpenAI provided a dangerously defective version of the chatbot. (NPR)

8 Apple is reportedly close to giving up on the Vision Pro
After the latest model flopped. (MacRumors

9 Senators are interrogating US AI firms on safeguards against China
Over fears of IP theft. (Axios)

10 Friendly AI chatbots are more likely to be inaccurate
A new study found kinder answers contained more mistakes. (BBC)

Quote of the day

“Never talk about goblins, gremlins, raccoons, trolls, ogres, pigeons, or other animals or creatures unless it is absolutely and unambiguously relevant to the user’s query.” 

—OpenAI instructs Codex to avoid critter talk in a system prompt for the coding agent, Ars Technica reports.

One More Thing

illustration of a house with numbered features

ARTHUR MOUNT


Is this the most energy-efficient way to build homes?

When engineers began designing an ultra-efficient home in the 1970s, they realized the trick wasn’t generating energy in a greener way, but using less of it. They needed to make a better thermos, not a cheaper coffee maker.

That idea helped inspire today’s passive-house standard: airtight buildings that can cut energy use by up to 90% through better windows, insulation, and ventilation.

Although they’re often considered a cold-climate approach, passive houses actually have universal benefits. Find out what makes them so efficient.


—Patrick Sisson

We can still have nice things

A place for comfort, fun and distraction to brighten up your day. (Got any ideas? Drop me a line.)

+ Finally, someone built a gaming PC inside a microwave that runs DOOM.
+ Experience the rhythm of the city through this rapid-fire collage of urban photography.
+ Get a dose of pure cuteness as these tiny snow leopard cubs leave their den for the first time.
+ If you’re staring at a random assortment of groceries, SuperCook will find a recipe based on what’s already in your pantry.

Artificial intelligence-based analysis of visual electrophysiological signals for clinical interpretation support

IntroductionVisual electrophysiology, including electroretinograms (ERG) and visual evoked potentials (VEP), provides a real-time functional assessment of retinal and post-retinal pathways, complementing structural imaging. Subtypes such as transient, periodic, multifocal, and code-modulated signals probe distinct physiological mechanisms and reveal pathological signatures ranging from photoreceptor dysfunction to cortical pathway impairment. However, interpretation is often challenged by low signal amplitude, noise, and inter-individual variability. Advances in artificial intelligence (AI) enable automated, objective and reproducible analysis, and may improve sensitivity, and scalability in clinical and research environments. We undertook a literature review to identify the potential of automated analysis of brief visual electrophysiology signals to support medical interpretation in ophthalmology.Materials and methodsA review of the 2020–2025 literature was undertaken.ResultsAI has been increasingly applied to ERG and VEP signals. These signals encode complex pathophysiological processes. Their features vary widely as they are transient (triggered by a single stimulus), periodic (repeated over time), multifocal (capturing signals from multiple visual field locations), or dependent on specific timing or coding schemes. These properties influence the choice of the most appropriate AI method for analysis. Classical ML methods remain useful for interpretable, feature-based classification of relatively scarce medical data, such as transient/aperiodic VEP and ERG. By modeling latent dynamics, AI can identify subtle or early dysfunction and harmonize interpretation across centers.ConclusionAI supports reproducible, clinician-independent pipelines for electrophysiology, well-suited to high-volume clinics and large-scale screening. The convergence of standardized acquisition protocols with advanced AI analysis has the potential to deliver more personalized, timely, and objective assessments of visual system integrity in neuro-ophthalmic practice.

Clinical application of 1H MRS in the human brain at 7T

Proton magnetic resonance spectroscopy (1H MRS) enables non-invasive biochemical sampling of tissues, potentially aiding diagnosis, prognosis and monitoring of various pathologies, while providing novel imaging biomarkers. Ultra-high-field (UHF) imaging at 7 tesla (7T) benefits from improved spectral dispersion due to an increase in chemical shift differences between metabolites, and a higher signal-to-noise ratio (SNR), making 1H MRS at 7T a particularly promising diagnostic tool for identifying and separating metabolites not clearly resolved at lower field strengths. However, 1H MRS at UHF presents technical challenges related to the short RF wavelength at 7T, resulting in B1 transmit field inhomogeneity, and the increased magnetic susceptibility gradients leading to B0 field inhomogeneity. Appropriate MRS methods are required to address these issues. In this article, we describe the technical aspects and challenges of 1H MRS at 7T, based on the experience in our centre, where single voxel 1H MRS has featured prominently in clinical 7T research applications for several years. We present data from six patients with glial tumours, including three who were post-operative, in whom post-surgical metalware affects the specific absorption rate (SAR), along with two patients with neuroinflammatory conditions and two with neurodegenerative diseases. The potential clinical use of 1H MRS for these pathologies and its possible integration as a promising biomarker into advanced imaging pathways are discussed.

A novel music-based real-time fMRI neurofeedback interface modulates interhemispheric connectivity and enhances mood

IntroductionMusic is a universal language that transcends cultures and is deeply rooted in human evolutionary history. Its creation and appreciation recruit the limbic and reward systems, leading to the evocation of emotions ranging from happiness and sadness to tenderness and grief. Here, we investigate the potential of music as an interventional tool in a novel neurofeedback connectivity-based experiment. MethodsThis study proposes a musical interface for real-time functional magnetic resonance imaging neurofeedback that is adaptable to diverse experimental paradigms, namely the ones aiming at improving mood and other affective dimensions. Using a previously developed motor imagery connectivity-based approach, we evaluate its feasibility and efficacy by comparing the modulation of bilateral premotor cortex activity during functional runs with real versus sham (random) feedback in 22 healthy adults. We also assess its performance against a visual feedback interface. The experiment involves a 50-minute MRI session, including anatomical scans, a premotor cortex functional localizer run, and four neurofeedback runs (two with active feedback and two with sham feedback). Pre- and post-session questionnaires assess the neurobehavioral impact on mood, musical background (as a potential predictor of neurofeedback success), and subjective feedback experiences. During neurofeedback, participants perform motor imagery of finger-tapping, with feedback delivered as a dynamic, pre-validated chord progression that evolves or regresses based on the functional connectivity between left and right premotor cortex.ResultsWe found that our implementation of music-based feedback was successful, with participants managing to modulate their own connectivity using the proposed interface. The modulation performance was similar for active and sham runs, possibly due to the power of music to boost neuromodulation, but the network recruitment was stronger for active neurofeedback, including in the insula, putamen, and target regions of interest. Behaviorally, we found a decrease in tension and an improvement in the overall mood of the participants after the session. DiscussionWhen comparing our results to previous neurofeedback data with a visual interface, we found stronger brain activations, in particular in neurofeedback-relevant regions such as the insula and the putamen. This work shows that it is possible to directly modulate interhemispheric connectivity using a real-time functional magnetic resonance imaging musical interface with potential effects on mood and recruitment of saliency and learning networks.